Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus  

作　　者：Hu XU Wen-Zhe CAO Yong-Yi BAI Rui-Hua CAO Lei TIAN Feng CAO Li FAN 

机构地区：[1]Chinese PLA Medical School,Chinese PLA General Hospital,Beijing,China [2]Department of Cardiology,the Second Medical Center,National Clinical Research Center for Geriatric Diseases,Chinese PLA General Hospital,Beijing,China [3]Institute of Geriatrics,the Second Medical Center,Chinese PLA General Hospital,Beijing,China

出　　处：《Journal of Geriatric Cardiology》2021年第6期440-448,共9页老年心脏病学杂志（英文版）

基　　金：This study was supported by the National Nature Science Foundation of China(No.81870249&No.81900409&No.91939303);the National Key R&D Program of China(2016YFA0100903);the Key Project of Chinese Military Health Care Projects(18BJZ32);the Science Foundation of the Chinese PLA General Hospital(2018XXFC-9);the Medical Big Data Project of Chinese PLA General Hospital(2018MBD-026).

摘　　要：OBJECTIVE To investigate the effects of sodium-glucose cotransporter 2 inhibitors(SGLT2i)on cardiovascular outcomes in elderly Chinese patients with comorbid coronary heart disease(CHD)and type 2 diabetes mellitus(T2DM).METHODS A retrospective cohort study was conducted on 501 elderly inpatients(≥60 years)with comorbid CHD/T2DM in Department of Cardiovascular Medicine and Endocrinology,Chinese PLA General Hospital from January 2018 to December 2019.These patients were divided into two groups according to the administration of SGLT2i.All the demographic characteristics and clinical data were collected.Cardiovascular outcomes,including all-cause mortality,major adverse cardiovascular events(MACE),and hospitalization for heart failure(HHF),were followed up.RESULTS In the cohort,there were 167 patients in the SGLT2i group and 334 patients in the control group.In the efficacy analyses,the incidence of MACE was lower in the SGLT2i group than in the control group:3.6%vs.9.3%(P=0.022).A lower risk of MACE was observed in the SGLT2i group[hazard ratio(HR)=0.40,95%CI:0.17-0.95].There was no significant difference in the incidence of all-cause mortality or HHF between the two groups.No significant difference of HR was observed for all-cause mortality(HR=0.41,95%CI:0.12-1.41)or HHF(HR=0.58,95%CI:0.12-2.81).CONCLUSIONS SGLT2i treatment exhibited benefits for elderly patients with comorbid CHD/T2DM with a lower risk for MACE.

关 键 词：patients MORBID MORTALITY 

分 类 号：R541.4[医药卫生—心血管疾病] R587.1[医药卫生—内科学]